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Pneumonia and other lower respiratory tract infections (LRTI) are major public health 
problems[1]. World-wide, LRTIs are the third leading cause of death and the mortality 
rates have remained unchanged for decades[1]. Furthermore, community acquired 
pneumonia (CAP) is a major cause of hospital admission, especially in the elderly[2].
At the current level of methodological development, the frequent lack of exact 
etiological information to guide a rational choice of treatment is a major concern, 
especially when considering the high mortality rates associated with CAP[3, 4].
Another consequence of insufficient etiological diagnosis in LRTIs is that the true 
efficacy of vaccines against respiratory tract infections is impossible to assess directly
[5, 6].
Norway is one of the few countries in the world where microbial resistance to major 
antibiotic groups such as penicillins, cephalosporins and macrolides is rare. For 
example, in 2010, 3% of  Streptococcus pneumoniae isolates from Norwegian blood or
spinal fluid culture were resistant to penicillin G, and concomitant resistance to 
cephalosporines was even more unusual (3/730 isolates) [7]. In most European 
countries, resistance to antibiotics is common among respiratory pathogens and
therefore, Norwegian guidelines for antibiotic treatment in respiratory infections differ
from most of those provided in the rest of Europe [8, 9].
Elderly patients are at increased risk for acquiring a respiratory infection. For patients 
above 65 years of age, the incidence of pneumonia is four times higher than in the 
population at large [10]. With a rapidly growing geriatric population, the number of 
patients suffering from pneumonia is estimated to double during the next thirty years
[11]. This will have a strong impact on the Norwegian health care system, including 
far-reaching logistical and economic consequences. 
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4.1. Bacterial infections
Severe pneumonia most commonly affects the oldest, the youngest and the immune-
suppressed individuals in our community.  The mortality in pneumonia is high, from 
2006 to 2010 almost 9000 individuals died from LRTI in Norway[12]. In 2008, 
approximately 200 000 died from LRTI in Europe[13], whereas worldwide, respiratory 
tract infections are responsible for an estimated 3.6 million deaths each year [14].
In order to ensure specific and timely antimicrobial therapy, etiological diagnosis is
essential for a successful outcome in pneumonia [15]. However, the anatomically 
shielded location of the lungs prevents direct access to the infected area using 
conventional tools for microbial sampling. Thus, the pathogen remains unknown in 
80% of hospitalized patients and 90 % of outpatients [16]. Insufficient knowledge of 
the pneumonia etiology frequently results in inappropriate treatment, which is a 
problem not only for the individual patient, but ultimately also for the society as a 
whole. In fact, the major driving force for the evolution of antimicrobial resistance is 
the indiscriminate use of broad spectrum antibiotics[17]. For example, multi-resistant 
strains of S.pneumoniae are an increasing concern globally [18].
In CAP the efficacy of conventional methods rarely exceeds 50 % [1, 19].
This etiological problem related to CAP has clinical implications as the value of
treatment recommendations depends on type of prevailing pathogens and their 
resistance to antimicrobials. Furthermore, the current limitations in our diagnostic 
arsenal results in inadequate knowledge on the extent and importance of mixed viral 
and bacterial infections and on the role of viruses alone in the etiology of CAP.
Lung infections caused by anaerobes are now believed to be the result of aspiration, or
bacterial colonization while on respirator or occasionally the cause of pulmonary 
abscesses [20, 21]. However, data obtained in the late 80’s using trans-tracheal
aspiration (TTA) revealed that anaerobes were responsible for at least 30 % of 
CAPs[22]. Some authors believe anaerobic lung infections often are misdiagnosed as
“atypical bacterial infections” such as Mycoplasma pneumoniae, Chlamydophila 
penumoniae or Legionella-species[22, 23].
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In Norway, only a few studies on respiratory pathogens have been performed (Table I)
in adults and elderly individuals. The majority of these studies have been based on 
agent identification through culture or anti-body analysis. All but two of the studies 
were performed more than 30 years ago. To our knowledge, no such etiological studies


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































More than twenty viral species are currently known to cause acute respiratory tract 
infections in humans. The incidence rates of these viruses vary by season and may 
assume a biennial fashion [32]. Respiratory viral infections (RVIs) are potentially 
serious illnesses with mortality rates up to 55% in the elderly, particularly in patients 
with underlying heart or lung disease [33]. In the older age groups, influenza virus, 
Respiratory syncytial virus (RSV) and Human metapneumovirus (HMPV) are 
responsible for the most serious infections [34].
However, - the clinical characteristics of RVIs in the elderly may not be representative 
of typical disease manifestations in younger age groups. It is conceivable that a silent 
epidemic could remain unrecognized in long term care facilities, as symptomatic 
patients are rarely examined for respiratory viruses. American and Canadian 
researchers have performed a few studies showing that 36-41% of the residents in long
term care facilities undergo at least one RVI each year [34, 35]. Several papers 
describe limited outbreaks with mortality rates of 0-50% [34, 36-39]. In Norway, no 
epidemiological, clinical or virological studies have been conducted to investigate the 
impact of respiratory virus infections in long time care facilities.
Of the RVIs, influenza virus is most extensively studied and influenza A and B viruses 
(InfA and InfB) are among the few respiratory viruses for which specific treatment is 
available.  The incidence of influenza-like illness varies from season to season; as 
much as 40 % of the Norwegian population might have been infected with InfA and 
InfB in years with high influenza activity (Figure 1) [40]. Mortality rates (Figure 2)
depends on the virulence of the seasonal influenza subtype, as well as on the level of 
specific immunity in the population. Disregarding the H1N1 pandemic where mainly 
individuals under 60 years of age were infected and on rare occasions died, the 
majority of influenza-related deaths are found in the older age groups [41]. For other 
types of respiratory viruses, less is known about incidence and mortality in different 
age groups, in particular among elderly individuals.
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Vaccines are available for influenza virus, but the number of elderly patients achieving 
vaccine induced protection could be as low as 30 % [42] or even virtually absent [43].
This is mainly due to altered t-cell function (see section 4.4.). Vaccines for RSV have
been in development since the 1960’s, but several trials have stranded either because 
of safety concerns or due to low vaccine efficacy[44]. A vaccine against respiratory 
infections caused by adenovirus was recently introduced, primarily for use among US 
military recruits[45]. For other viruses, no vaccines appear to be in advanced stages of 
development[46].
16
Figure 1. Yearly incidence of influenza-like illnesses in Norway 2006-2012, as 
reported by the Norwegian Institute of Public Health.
[47]
Figure 2. Number of registered deaths from influenza infections in Norway 2002-
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4.3. Sample harvesting
Essential for the etiological diagnosis of an ARI is recovery of representative test 
samples without contamination. Several possible sampling methods are available
(Table II).
In most cases of LRTIs, specimen recovered through the mouth or nose substitute for 
specimens collected directly from the affected area. Unfortunately, the diagnostic 
value of such samples is dubious, as in the nose and mouth contamination by potential 
irrelevant pathogens such as Haemophilus influenzae, Moraxella catharralis, 
Streptococcus pneumoniae and anaerobes is practically unavoidable [49-51].
Although in CAP, a positive blood culture is the most important etiological proof,
blood cultures are positive only in approximately 30 % of  the cases [52]. Paired serum 
antibody tests are sometimes helpful, but usually results are available only after a 
couple of weeks, which is too late for guiding the initial choice of antibiotic treatment.
Urinary antigen tests are available for S. pneumoniae and Legionella pneumophila
serotype 1. Although the sensitivity of such tests is high [53, 54], interpretation of 
positive results may be difficult as the actual urinary antigens may be detectable for up 
to a year after the initial infection [55, 56].
Conventional diagnostic measures including culture of blood and sputum, urinary 
antigen tests, upper respiratory swabs and serology are all indirect approaches to the 
etiological diagnosis of ARIs and both positive and negative results obtained with 
these methods require skilled interpretation[4].
Transthoracic fine needle aspiration (TFNA), first published in 1883, is an old method
for diagnosis of pulmonary infections [57]. The technique was in common use in the
pre-antibiotic era when treatment of pulmonary infections was mainly by 
pneumococcal antiserum. During the 1980-90s, the introduction of polymerase chain 
reaction (PCR) methods stimulated new interest in TFNA (Table III). Having localized 
the pneumonic infiltrate radiologically, TFNA is performed with a syringe and an 
ultrathin needle that is inserted directly into the infectious area in the lung, thus
bypassing potential contamination from the oropharynx. Most TFNAs have been done
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bedside, without radiological guidance [58]. The main adverse events of TFNA are 
pneumothorax and hemoptysis. Two large reviews of TFNA, one including  3560 
children and the other over 3000 adults, reported incidences of pneumothorax of 3.2%
and 3.3% respectively[52, 58]. Chest drainage was needed in 0.5% of the cases [52,
58].  Minor hemoptysis was by some authors reported as common[52], but was not 
mentioned in other studies. There was no report of empyema in any of these studies. 
Trans-tracheal aspiration (TTA) as a method of specimen collection in lower 
respiratory airways was first published by Pecora in 1959[59]. The method was later 
modified by Kalinske[60] and was mainly use between 1960-1980 for research 
purposes. With the patient in a supine position, local anesthetics was applied to the 
cricothyroid membrane and the aspiration carried out using a needle guided 
catheter[61]. In Norway, this method was used by Schreiner et al. in the 1970s and 
1980s to investigate the etiologies of CAP, anaerobic respiratory infections, chronic 
bronchitis and bronchiectasies, respectively [24-27]. The major side effects of this 
procedure are coughing, subcutaneous emphysema and hemoptysis [22, 62]. In one 
study of 25 patients with CAP, microbiological specimens were sampled with both 
TTA and TFNA[63]. In 20/25 of these patients, an etiological diagnosis was 
established by TFNA, whereas TTA and TFNA revealed the same pathogens in only
9/22 (41%) of the patients. Contaminations by oral flora was suspected in 11/22(50%)
of  the TTA samples [63]. This finding is in contrast to other reports claiming tracheal
sterility when not suffering from a respiratory infection [62, 64, 65]. The patients who























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   











































































































































































































































































































































































































































































































































































































4.4. Infection and immunity in the elderly
Elderly individuals have a higher susceptibility to, and are at increased risk of dying 
from infections such as pneumonia, urinary tract infections and skin infections[95]. An
atypical clinical presentation, such as lack of fever is a common feature of infections 
in the elderly [96], and the causative pathogens are more diverse in older age groups
than in younger individuals. This emphasizes the importance of arriving at an 
etiological diagnosis and to initiate proper and timely treatment in patients aged > 65 
years.
Aging of the immune system, also known as immunosenescence, is characterized by 
unfavorable alterations in numbers, types, receptor density and cytokine production of 
the immune cells [97-99]. However, biological age does not seem to be the only 
indication of an immunosenescent state. Individual genetic factors, frailty, persistent
cytomegalovirus infection and comorbidities may all influence the risk of reduced 
immune function [99, 100]. In practical terms, immunosenescence is reflected by the 
fact that in at least 50-70% of the influenza vaccinated elderly above 75 years of age 
protection is not achieved against the actual influenza strains [101] and that the widely 
used 23-valent pneumococcal capsular polysaccharide vaccines is hardly of any use in 
this age group [102]. On the other hand, approximately 30% of the elderly display T-
cell populations (CD8+CD45RO+CD25+) where the T-cell functions are at the same 
level as in younger adults, including retained ability to diversify and mount a sufficient 
immune response when infected[99].
The concept of inflamm-aging was proposed in 2000 by Franceschi et al[103],
recognizing that factors other than age may have significant influence on the immune 
system. Inflamm-aging is a condition whereby chronic activation of the innate 
immune system leads to several specific changes such as increased levels of MK cells 
and interleukins. These alterations are beyond and above the effects of 
immunosenescence. Inflamm-aging is claimed to have a genetic and an environmental
component, rendering a potential for improvement by environmental interventions
[103].
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The ability to mount a sufficient antibody response and sustain durable antibody levels 
above a certain threshold after vaccination is crucial for vaccine efficacy. Following 
vaccination, the early protective efficacy is primarily conferred by the induction of 
antigen-specific antibodies. Antibody avidity is another important factor of efficacy 
and long term protection requires the generation of immune memory cells capable of 
rapid and effective reactivation upon subsequent microbial exposure. The predominant 
role of B cells in the efficacy of current vaccines should not overshadow the 
importance of T cells responses: T cells are essential to the induction of high-affinity 
antibodies and immune memory effectors [104].
The outcome of booster vaccination is in part dependent on the level of pre-booster
antibodies [101] [105]. Ideally, in order to obtain long term protection in the elderly, 
vaccination against novel pathogens should be performed in the pre-immunosenescent 
state, when an adequate antibody-response can be mounted[101]. However, such 
preemptive priming of the immune system would be particularly problematic against 
agents such as InfA virus, where frequent antigenic changes could render previously 
obtained protection useless. Novel approaches such as vaccines based on protein
antigens shared by all InfA strains, increased dose of vaccine antigens, intradermal 
vaccinations and optimal adjuvants might improve protective immunity in the 
elderly[106-110]. In addition, alternative vaccination schedules, primarily an increased 
number of injections for the elderly, are being tested [111]. Today, apart from high age
and documented immunodeficiency, there are no markers able to identify likely non-
responders to immunization.
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5. Status of knowledge before study initiation
Since the late 1990’ies, real time PCR has been frequently used for identification of 
respiratory pathogens. More recently 16S rDNA/rRNA PCR methods were introduced  
for the identification of unknown pathogens. Compared with traditional methods such 
as bacterial and viral cultures, these PCR techniques allow rapid and in some cases 
more sensitive pathogen identification. 
At the time of study initiation, samples for investigating lower respiratory tract 
infections were harvested mainly by the use of bronchoscopic techniques, swabs or by 
the induced sputum method. Using these methods, there is a high risk of sample 
contamination by irrelevant oropharyngeal flora and therefore interpretation of the 
results could be difficult.  During the 1990’s several studies were published on the use 
of TFNA in combination with real time PCR to increase the diagnostic gain in cases 
of CAP [82, 87, 88, 92, 112, 113]. However, no studies had used 16S rDNA/rRNA
PCR techniques together with TFNA. 
For decades, nasopharyngeal and oropharyngeal swabbings to recover the infectious 
agents combined with paired blood samples for antibody analysis have been the
conventional tools to obtain an etiological diagnosis in upper respiratory tract
infections. For RVIs, the WHO guidelines recommended a combination of 
nasopharyngeal(NP) and oropharyngeal (OP) sampling [114]. Alternative sample 
harvesting procedures included nasal washes and aspiration, but these methods have
been difficult to implement in frail elderly [32].
At the time of study initiation no age-specific harvesting recommendations for 
respiratory viruses were available. In addition, the number of publications on viral 
infections in elderly subjects was scarce, and in most cases studies were performed by 
the use of immune-fluorescence techniques, rapid serological tests or serum antibody 
measurements. Little was known on the incidence and importance of respiratory viral
infections in older age groups and in particular, no published studies had compared the 
viral load in the OP and NP of elderly individuals using swabbed mucosal specimens.
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At the time of study initiation, two structurally different swab types were available for 
viral and bacterial sampling; flocked swabs and rayon swabs. Theoretically, the type of 
swab could influence both the ability to retain pathogens at the actual anatomical site,
and subsequently to release the pathogens from the swab for further analysis in the 
laboratory. No comparative studies on viral yield had previously been performed 
between these swabs.
Early diagnosis of influenza based on rapid laboratory tests had been shown to shorten 
the length of stay among hospitalized children and middle aged adults [115] [116].
Additionally, in children early diagnosis of influenza was found to decrease the use of 
antibiotics [115]. No such studies had been performed in elderly age groups.
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6. Objectives
The main objectives of this thesis were to assess whether:
1. investigational trans-thoracic fine needle aspiration for the etiological diagnosis of 
pneumonia is feasible and safe in adults with confirmed CAP.
2. there is a difference in respiratory viral load between mucosal specimens collected 
from the nasopharynx and the oropharynx.
3. the two swab types differs in viral retaining capacity when investigating respiratory 
viral infections in the elderly
4. routine real time PCR for respiratory viruses influences length of stay and 




Aust-Agder County, located in southern Norway, has approximately 111 000
inhabitants. Approximately 67 % of the population is living in densely populated areas 
and 21 % are 60 years or older [117]. In Aust-Agder, the mean individual income after 
taxes was NOK 283 600 in 2001 [117].
Vest-Agder County has a population of 175 000 inhabitants. Approximately 81% of 
the inhabitants are living in densely populated areas, 20% are 60 years or older. In 
Vest-Agder, the mean individual income after taxes was NOK 281 300 in 2001 [117].
Paper I: The 20 study subjects were recruited from patients hospitalized with CAP at 
the Medical Department, Sorlandet Hospital Arendal HF. An average of 212 patients
were admitted to the Medical Department each year in the period 2008-2013 with
lower respiratory tract infections[118].
Paper II and IV: The 223 study subjects were recruited from patients aged above 60
years and admitted to the Medical Department of Sorlandet Hospital Arendal.
Approximately 5714 patients are admitted each year to the Medical Department[118].
Paper III: The 32 study subjects were recruited from the population of patients testing
positive for Influenza A or B at Sorlandet Hospital Arendal HF and Sorlandet Hospital 
Kristiansand HF during the study period.
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7.2. Obtaining brush specimens for viral diagnosis
The following procedures were used when swabbing for respiratory viruses.
Oropharyngeal swab samples were collected from the tonsils or posterior OP area by 
applying medium pressure on the swab. A tongue depressor was used during the 
procedure to avoid touching the tongue with the swabs. 
Nasopharyngeal swab samples were collected by carefully inserting the swab as far 
as possible into one nostril, rotate 360 degrees and then withdraw.
The patients were informed in advance that local irritation from the swab could result 
in sneezing or tear-formation. In patients with international normalized ratio (INR)
above 3, NP samples were not harvested due to increased risk of nasal bleeding.
Table IV. Types of swabs used for viral specimen harvesting
Immediately after the procedure, the rayon swabs were inserted into the Virocult
medium and the tip of the tube squeezed as instructed by the manufacturer. The nylon 
flocked swabs were inserted into Universal Transport Medium (UTM) tubes (1.5 ml 
medium, no beads, Copan Italia) and the tubes were shaken for 10 seconds. Only one 
swab was used per transport tube, regardless of type of swab or location swabbed. The 
Oropharynx Nasopharynx







Paper III 502CS01 regular2,b 503CS01 nasopharyngeal2,b
1Virocult, Medical Wire & Equipment, England, 




tubes were stored at room temperature and transported to the microbiological 
laboratory within 48 hours.
The study subjects in paper I underwent mucosal swabbing in the oropharynx at the 
time of inclusion into the study (within 36 hours after hospitalization). A total of two 
OP swabs were used, one on each tonsillary area. 
The study population of paper II and IV underwent mucosal swabbing the day after 
hospitalization. Four weeks later, all patients testing positive for a respiratory virus 
were retested using the same procedure. A total of four swabs were used per patient.
The swabbing was performed in the following order: Right oropharyngeal area, left 
oropharyngeal area, left NP and right NP.  The order of application of the two types of 
swabs used was decided by block randomization. 
The patients included in paper III were swabbed on average (SD) 1.5 (±0.8) days after 
hospital admission. In this study, only patients testing positive for influenza virus at 
the time of hospital admission were eligible for inclusion. For each patient, one 
flocked swab was used in the NP and one flocked swab in the OP.
34
7.3. Viral load
Isolation of nucleic acids and the subsequent real time PCR examinations are 
described in details in paper I-III.
Viral load is the estimated viral concentration in a sample.  The viral load is dynamic 
and varies throughout the course of the infection. Studies on influenza reveals
variable viral load- and shedding patterns depending on the patients’ age, 
comorbidities and vaccination status, as well as on influenza subtype. The viral
concentration in a sample may be measured directly by the use of flow-cytometric 
methods, enzyme-linked immunosorbent assays (ELISA) or by the use of fluorescent 
assays or culture [119]. Another possibility is an indirect estimate by calculating the 
difference between two or more samples using cycle threshold (CT) values. During 
PCR amplification the amount of DNA is doubled in each cycle until the components 
in the reaction reaches a critical level. There is an exponential relationship between the 
initial amount of template DNA and the CT values. A high CT value represents a low 
microbial load in the specimen and vice versa. The differences in CT-values obtained 
from different samples included in the same experimental run demonstrate a relative 
difference in concentration between samples. Samples that differ by a factor of two in 
the original DNA concentration would be expected to be one cycle apart in the run, 
whereas samples that differ by a factor of ten would be approximately 3.3 cycles apart.
Viral load calculations by cycle threshold comparisons was our method of choice as it 
is precise, cost effective and can be performed locally.
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7.4. Transthoracic fine needle aspiration
Transthoracic fine needle aspiration was used in paper I as a method for harvesting 
microbiological samples from the infectious area of the lung.
Routine chest x-ray upon admission and subsequent fluoroscopy guided the choice of a 
suitable site for the needle puncture. The puncture site was anaesthetised for one hour
using a lidocain 25mg/prilocain 25 mg patch (Emla, AstraZeneca AB Södertälje, 
Sweden). The area was then washed aseptically with iodide solution and a sterile 
dressing was applied. A 22 gauge needle (Spinocan-R, B Braun Melsungen AB, 
Melsungen, Germany), stylet removed, was attached to a 10 ml syringe containing 5 
ml isotonic saline.
Under fluoroscopic guidance the needle was introduced into the pulmonary infiltrate 
(common location 3-6 cm from lung surface) while the patient was breathing 
shallowly or briefly suspending breathing. Four ml of isotonic saline (sterile water was 
used in the first 6 cases) were injected into the area of pulmonary inflammation, 
leaving 1 ml as carrier fluid in the syringe to safeguard diagnostic minimum 
procedures even with sparse material. Negative pressure was applied while the needle 
was slowly retracted. Chest x-rays in both inspiration and expiration were taken 1-2
hours after the TFNA-procedure to detect possible pneumothorax or intrapulmonary 
bleeding. The procedure was performed within 36 hours of hospital admission, 
ongoing or previous antibiotic treatment were not a reason for exclusion.
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7.5. Assessment of comorbidity
Multimorbidity is common in the geriatric population. To establish a robust measure 
of the study participants coexisting illnesses, two comorbidity scales were used in 
paper IV.
Charlsons comorbidity index (CCI), originally developed in 1984 as “taxonomy for 
comorbid conditions that might alter short term mortality” [120]. CCI is the single 
most used comorbidity scale in the world; however generalization based on CCI may 
be difficult due to the composition of the initial study population and the elapsed time 
since its scale development [121].
Cumulative illness rating scale (CIRS-G) was developed in the 1960’s[122], and 
subsequently modified several times for geriatric use (CIRS-G) [121, 123, 124].
Initially CIRS were designed to assess physical impairment and as a tool for medical 
prognosis [122].
Whereas the CIRS-G is based on the rater’s judgment of severity based on instructions 
from the accompanying manual, the CCI uses explicit criteria for rating. The definition 




In this thesis, SPSS 16.0 or higher were used for statistical analysis. 
Throughout the papers, Students t-test was used when comparing continuous data, 
Chi-square when comparing categorical data.
In paper II, linear mixed model analysis was used when comparing calculated viral 
load in sampling sites and different swab types as the variables were not independent 
of each other.
In paper IV, Cox regression was used for length of stay analysis. CIRS-G domain 
scores were analyzed as categorical variables, whereas total CIRS-G and CCI scores 
were analyzed as continuous variables [121].
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9. Synopsis of the papers 
Paper I: Transthoracic fine-needle aspiration in the aetiological diagnosis 
of community-acquired pneumonia
Objectives: To assess safety and feasibility of TFNA in CAP




1. Chest x-ray upon admission showed infiltrate suggestive of 
pneumonia and
2. One or more of the following findings: cough, fever > 38°C,
productive sputum, dyspnoea or CRP > 50 g/L.
Exclusion
criteria:
One or more of the following:
Age <18 years, pregnancy, INR > 1.8 or platelets < 50 G/L, chronic 
lung disease with FEV1 < 50% of predicted value, large 
emphysematous bullae, pO2 on arterial blood gas below 8 kPa, 
inability to give informed consent or cooperate, incontrollable 
cough, patients in need of respiratory assistance. Patient unwilling to 
participate.
We conducted TFNA under fluoroscopic guidance on 20 CAP patients within 36 hours 
of hospitalization. The procedure was easy to perform and the discomfort to the 
patients was minimal. There were no serious adverse events. Two patients developed 
minor, self-limiting pneumothorax and seven patients reported pin-point sized 
haemoptysis.
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The CAP-aetiology was considered definite if based on 1) a positive culture from lung 
aspirate or blood and/or 2) a positive result of PCR on lung-aspirate and/or 3) a 
significant serological rise in the IgM/IgG levels, according to the respective 
manufacturers’ definition of a positive test. The aetiology was considered presumptive 
when 1) an established lung pathogen was found by sputum culture, and/or b) an 
established lung pathogen was detected by PCR on oropharyngeal swabs, and/or a 
positive antigen test for L. pneumophila or S. pneumoniae were obtained in the urine.
A definite aetiology for CAP was established in 12/20 (60%) of the patients; in 8/20 
(40%) by TFNA alone. When including presumptive aetiologies we established an 
aetiological diagnosis in 14/20 (70 %) of the patients.
The main conclusion from this study is that TFNA is a safe sampling procedure. 
Combined with modern microbiological methods TFNA may provide important 
additional information on the aetiology of CAP.
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Paper II: Swabbing for respiratory viral infections in older patients: a
comparison of rayon and nylon flocked swabs
Objectives: To compare the sampling efficacy of rayon swabs and nylon flocked 
swabs, and of oropharyngeal and nasopharyngeal specimens for the 
detection of respiratory viruses in elderly patients.
Population: 223 patients hospitalized at Sorlandet Hospital Arendal HF, Norway
Inclusion
criteria:
1. Born 1948 or earlier (60 years or older).
2. At least one of the following symptoms with onset less than three 
weeks ago: Nasal congestion or runny nose, throat pain, fever,
malaise, muscle pain, self-diagnosis of “the common cold”, 




INR 3.0 or more
Patient (or next of kin on behalf of the patient) unwilling to 
participate.
In recent years, respiratory viruses have been established as significant causes of 
mortality and morbidity in the older population [36, 39, 125-127]. However, as
different respiratory pathogens may cause similar clinical pictures etiological 
diagnosis depends on laboratory confirmation [128].
As demonstrated with RSV, viral detection is more demanding in the elderly than in 
young individuals, as older people tend to shed less virus and have shorter viral-
shedding periods [129]. Hence, rapid viral antigen tests that are useful in children may 
fail in the elderly[66]. Due to its high sensitivity and specificity, real-time PCR on 
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respiratory viral samples represents an important diagnostic opportunity also in the 
older age groups.
Two structurally different swabs are available for microbial sampling in the upper 
airways: rayon swabs and nylon flocked swabs. A few studies comparing the 
respective efficacies of these two swabs in providing viral diagnostic specimens have 
been performed in children, but to our knowledge, no such studies have been 
conducted in patients 60 years or older.  in the elderly.
Samples were obtained from patients 60 years of age or above, who were admitted 
within the last 24 hours to Sorlandet Hospital Arendal, Norway. The patients were 
interviewed for current symptoms of a respiratory tract infection after previously 
established criteria. Using rayon swabs and nylon flocked swabs comparable sets of 
mucosal samples were harvested from the nasopharynx and the oropharynx. The 
samples were analysed using real-time PCR methods for RSV, HMPV, InfA, InfB,
Adenovirus and Parainfluenza virus 1-4. To achieve a more complete diagnostic 
coverage of respiratory pathogens, PCR assays were added for the detection of
M.pneumoniae, C.pneumoniae, and B.pertussis.
223 patients (mean age 74,9 years, SD 9.0 years) were swabbed and a virus was 
recovered from 11% of the symptomatic patients. Regardless of sampling site, a 
calculated 4.8 times higher viral load (95% CI 1.3-17, p=0.017) was obtained using the 
nylon flocked swabs, as compared to the rayon swabs. Also, regardless of type of 
swab, a calculated 19 times higher viral load was found in the samples from the 
nasopharynx, as compared to the oropharynx (95 % CI 5.4-67.4, p<0.001).
We conclude that when swabbing for respiratory viruses in elderly patients 
nasopharyngeal rather than oropharyngeal samples should be obtained. Nylon flocked 
swabs appears to be more efficient than rayon swabs.
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Paper III: A comparison of nasopharyngeal and oropharyngeal swabbing 
for the detection of influenza virus by real-time PCR
Objectives: To assess the diagnostic yield of real time PCR for influenza virus 
infection following oropharyngeal as compared with nasopharyngeal 
swabbing.
Population: 32 patients admitted to Sorlandet Hospital Arendal HF and Sorlandet 
Hospital Kristiansand HF, Norway
Inclusion
criteria:
Positive real-time PCR for influenza at the time of hospitalization.
Patients above 18 years old.
Exclusion
criteria:
INR 3.0 or more
Patient or (next of kin on behalf of the patient) unwilling to 
participate.
During the local influenza season of 2009-2010 hospitalized patients who upon 
admission had tested positive for presence of influenza virus by real time PCR 
methods were prospectively asked to participate in this study.  Using flocked swabs, 
oropharyngeal and nasopharyngeal samples were harvested from all patients as soon as 
possible and no later than 3 days after the initial detection of influenza virus. Thirty-
two patients were included in the study, mean age 50.9 (± 22.8) years, median duration 
of symptoms prior to hospitalization 3.3 (±2.7) days. The patients were swabbed on 
average 1.5 (±0.8) days after hospital admission. Seventeen patients were diagnosed 
with Influenza B, fourteen patients with Influenza A (H1N1) and one patient with 
Influenza A(H3N2).
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The influenza seasons 2009-2011 were dominated by influenza B and influenza 
A(H1N1)pdm2009. In general, nasopharyngeal samples were positive at a lower CT 
value than oropharyngeal samples (mean difference CT 5.75 (95% CI 3.8-7.7) p<0.01) 
rendering a calculated 54 times higher (95% CI 13.7- 210.8) viral concentration in the 
nasopharyngeal samples. Calculations based exclusively on influenza A H1N1 strains 
suggests a 23 (95% CI 3.8-136.2, p<0.01) times higher mean viral concentration in the 
nasopharynx than in the oropharynx. For influenza B the calculated difference in mean 
viral concentration was 80 (95% CI 9.3 -694.6, p<0.01) times higher.
We conclude that in patients with acute influenza nasopharyngeal swabbing is superior 
to oropharyngeal swabbing in terms of diagnostic yield as assessed by real time PCR.
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Paper IV: No impact of early real time PCR screening for respiratory 
viruses on length of stay and use of antibiotics in elderly patients 
hospitalized with symptoms of a respiratory tract infection
Objectives: To examine whether a positive real-time polymerase chain reaction 
test for respiratory viruses influenced factors such as length of 
hospitalization and antibiotic prescription in patients above 60 years 
of age.
Population: 223 patients hospitalized at Sorlandet Hospital Arendal HF, Norway.
(Same as paper II)
Inclusion
criteria:
1. Born 1948 or earlier (60 years or older)
2. At least one of the following symptoms with onset less than three 
weeks ago: Nasal congestion or runny nose, throat pain, fever,
malaise, muscle pain, self-diagnosis of “the common cold”, 




INR 3.0 or more
Patient (or next of kin on behalf of the patient) unwilling to 
participate.
The burden of diseases caused by RVIs among elderly both in the community and  in 
hospitals is difficult to establish as symptoms often are nonspecific[130].  The high 
diagnostic sensitivity of real time PCR may be of special value in the elderly, who 
seem to be characterized by low viral shedding, at least in the case of RS-virus[129,
130].  In children, rapid tests for respiratory viruses have reduced the duration of 
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hospitalization, antibiotic prescription, and the cost of hospitalization [115, 131].
Similar findings have been observed in young and middle aged adults [116]. Limited
data is available on the effect of improved microbiological diagnostics in the elderly 
population [132].
A total of  interviewed for symptoms of an ongoing 
respiratory tract infection and 147 patients and the 56 controls were allocated into 1) 
symptomatic and PCR positive (S/PCR+); 2) symptomatic and PCR negative(S/PCR-);
or 3) no symptoms and PCR negative (Control) dependent on symptoms and 
microbiological findings.
The frequency of antibiotic treatment during hospitalization did not differ between the 
S/PCR+ and S/PCR- symptomatic cohorts (X2=0.49). In the S/PCR+ group sixteen out 
of nineteen patients received antibiotics during hospitalization whereas in the S/PCR-
cohort 99 out of 128 received antibiotics. When the PCR results became available, 
only two patients in the S/PCR+ cohort had their antimicrobial treatment discontinued. 
Four additional patients had CRP values below 100 mg/L and negative chest x-rays, 
and hence, the likelihood of an ongoing bacterial infection was low.  In the remaining 
ten patients, four had CRP values above 100 mg/L, two were diagnosed with chest x-
ray findings consistent with pneumonia, and four patients presented with both 
findings. In those patients, the possibility of an ongoing bacterial infection was 
relatively high.
In the length-of-stay analysis, a significant difference was found between the two 
symptomatic cohorts and the controls (p<0.001), but no difference were observed 
between the S/PCR- and S/PCR+ cohorts (p=0.39). When comparing total CIRS-G
scores and CCI scores, no difference between the three cohorts were found (p=0.29 
and p=0.15 respectively). A significantly higher proportion of category four CIRS-G
domain scores were found in the S/PCR- cohort (p=0.032) compared to the S/PCR+ 
cohort. When comparing the self-reported symptoms between the two symptomatic 
cohorts, a significant difference in self-reported symptoms between the two 
symptomatic cohort were found only for coughing (p=0.003) which was reported more 
often in the S/PCR+ than in the S/PCR- cohort. No significant difference between the 
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cohorts was found when comparing the number of days in intensive care and deaths 
during the next 12 months.
We conclude that in our general hospital setting, access to an early viral diagnosis had 




This section will first discuss methodological aspects of performing the study and then
our main findings. Finally, some ethical aspects of studying illness in acute ill elderly 
persons will be discussed.
10.1. Methodological aspects
10.1.1 Subjects included in the study The involved patients in this thesis were
mainly recruited from hospitalized individuals at Sorlandet Hospital Arendal HF,
although in paper III, sixteen patients from Sorlandet Hospital Kristiansand HF were 
included as well. Sorlandet Hospital Arendal HF is the only general hospital in Aust-
Agder County, Sorlandet Hospital Kristiansand HF is one of two general hospitals in 
Vest-Agder County. In 2008, the number of hospitalization days per 1000 inhabitants 
was 175.9 in Aust-Agder, and 168.1 in Vest-Agder. For Norway as a whole, the 
corresponding figure was 171.8[133].
In paper I, approximately 13 percent of the then hospitalized patients with 
radiographically confirmed CAP during the study period were included in the 
investigation. The majority of the non-eligible patients suffered from cognitive 
impairment, used anticoagulants or was diagnosed with COPD. Patients with cognitive 
impairment and/or using anticoagulants might be more susceptible for CAP but the 
general belief is that the pathogens are similar to those found in this study. COPD 
patients treated with steroids or who frequently receive antibiotics may have increase 
susceptibility for uncommon CAP-pathogens. Throughout this study, inability to give 
informed consent was a reason for exclusion. As elderly patients more often suffer 
from delirium both from the infection and from hospitalization itself, the proportion of 
elderly patients included in this study differs from the general population of hospital 
admitted elderly patients with CAP[134]. This methodological challenge is difficult to 
approach as long as TFNA is viewed as an experimental diagnostic measure. Studies 
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have revealed that dementia increases the risk of acute organ dysfunction and sepsis 
[135], which might explain why patients in advanced stages of dementia frequently 
dies from pneumonia[136]. Our results are thus representative only to the group of 
cognitively preserved elderly.
In paper II and IV the study population is likely to be representative for the hospital
population as a whole as the patients included were hospitalized for a variety of 
reasons. Paper III might represent a subgroup of the general population, as the 
included patients were already hospitalized for influenza infections.
We conclude that the subjects included in the current studies are representative of 
those eligible. As Norway is relatively uniform in terms of ethnicity and  
socioeconomic conditions, and the two involved hospitals are the only major hospitals 
in their respective counties, we expect the observations made in the present studies to 
be quite representative of the country at large.
10.1.2 Sampling
Viral sampling: The sampling procedures were performed by local technicians, after 
proper training. Care was taken to minimize the number of personnel included in 
sampling, in order to possibly reduce inadequate sampling techniques. 
TFNA: This procedure was performed by one doctor only to avoid inter-personnel 
variation.
10.1.3 Analysis: The biochemical analyses were performed by the Laboratory 
Department at Sorlandet Hospital Arendal and the Department of Microbiology 
Sorlandet Hospital Kristiansand, both departments accredited by the International 
Organization for Standardization. The amplification efficiency of the PCR assays 
performed at St.Olavs Hospital was estimated to be above 95 %. The amplification 
efficiency of the PCR assays used in paper II was estimated to be above 94 % and in 
paper III to be above 98%. Hence, it may be concluded that the quality of the specimen 
sampling and their subsequent analysis were adequate.
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10.2. Safety and feasibility of TFNA
Our knowledge of the microbiological flora in normal lungs and in lungs with ARIs is 
limited. The previous belief of a sterile lung below carina is now refuted and an
increased focus has been put on the local microbial flora (microbiota) of the lower 
respiratory tract, both as immunomodulators and as pathogens [137-141].
Better sample harvesting techniques in combination with multiplex PCR or 16 S 
rDNA/rRNA improves the possibility of detecting microorganisms. Harvesting 
techniques, such as bronchoscopic procedures, increases the risk of irrelevant 
colonization from the oro/nasopharynx  being transported to the lung parenchyma, thus 
leading to difficulties in distinguishing contaminants from pathogens[50]. This is 
especially important in CAP etiology research, where possibly irrelevant upper airway
colonization especially by H.influenza, M.catharrhalis and S.pneumoniae could lead to 
an erroneous etiological conclusion [49, 51]. The type of colonization might  be 
dependent on age, comorbidities and immune status; elderly patients have surprisingly 
low carriage rates of pneumococcus [51], but no thorough consensus has been reached
on actual figures.
No studies have been performed comparing the microbiological yield between samples 
obtained by bronchoscopic procedures and lung aspirates in combination with novel 
PCR methods. TFNA and TTA are the only available sampling methods bypassing the
oro/nasopharynx.  With increasing microbial resistance to antibiotics, better diagnostic 
methods for CAP are in high demand. As shown in paper I, TFNA is a feasible and 
efficient method to obtain material for the etiological diagnosis of radiographically 
confirmed CAP.  By combining conventional analyses of blood, urine and sputum with 
TFNA, the ability to etiologically diagnose a pulmonary infection increases from 50 to 
80% [89]. In addition, mixed pulmonary infections including those involving
anaerobes are more likely to be identified with this method. Although novel PCR 
methods such as 16 S rRNA/rDNA in theory increase diagnostic yield, in our 
experience the method is still not sufficiently sensitive at least as applied to lung 
aspirates. The amount of aspirate is small, and due to the intra-syringeal dilution of the 
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sample by the 1 ml sodium chloride carrier, the analysis is performed near the PCR’s 
lower detection limit. 
Our study has shown that TFNA is both safe and applicable also in our hospital 
setting, and should be considered in clinically difficult cases including treatment 
failure. The currently low level of antibiotic resistance in pathogens in Norway may 
imply that in our country, TFNA will be used mainly for research purposes. We 
suggest that new methods for the etiological diagnosis of CAP should be validated 
against clinical material recovered by TFNA.
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10.3. Superiority of nasopharyngeal swabs
At the time of our viral studies, a combination of intra-nasal and throat swabs were the
internationally recommended sampling methods[142]. In 2012, the WHO guidelines 
were altered to recognize the higher influenza viral load in nasopharyngeal samples by 
recommending the NP as the primary sampling site[143]. No recommendations are 
available with regard to swab type.
We found significant differences between sampling sites as well as between types of 
swabs, favoring nasopharyngeal swabbings and flocked swabs [144]. However, the
optimal sampling site, swab type and specimen material seem to vary with age. In 
children, the sensitivity of nasopharyngeal aspirates and mid-turbinate intranasal 
swabs are comparable for identification of common respiratory viruses, RSV excluded 
[145, 146]. In patients aged 18-69, no difference between intranasal flocked swabs and 
nasopharyngeal swabs were found, making self-sampling a possibility in this age 
group [147]. To our knowledge, no studies in the elderly comparing mid-turbinate 
intranasal swabs and nasopharyngeal swabs have yet been published.
Our finding that in elderly patients, the viral concentration in samples harvested with 
flocked swabs was 4.8 times higher than in samples harvested with rayon swabs is of 
considerable interest. The fact that in the elderly, the viral load is lower than in 
younger individuals [148] may possibly enhance the difference between these swab
types. This hypothesis is supported by a study in children with influenza A and B,
where rayon swabs and flocked swabs used in the nasopharynx performed equally 
well[149]. By recommending flocked swabs only, one ensures the best possible 
sampling method for the whole population
The difference between the NP and OP in terms of concentrations of influenza virus is
intriguing.  Influenza-hemagglutinin binds with a sialic acid (SA) galactose (GAL) 
linkage; influenza A seem to prefer SA-alpha2,6-Gal linkage[150]. These receptors are 
mainly found on ciliated goblet cells distributed from the nasal cavity to the bronchi
[151]. No studies have compared the receptor density between the OP and the NP
where theoretically a higher density might be found.  Age differences have been found 
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with regard to expression of different receptor types in the airways, but no such studies 
have been performed solely on the elderly[150].  Transfer serum IgG antibodies across 
mucous surfaces could possibly reduce the viral concentration, especially in the 
oropharynx [104]. In addition, other antiviral properties in saliva such as salivary 
agglutinin (gp340, DMBT1), lactoferrins, lysozymes and mucins could be partly 
responsible for the lower viral concentration in the oropharyngeal cavity [152].
Dilution and mechanical cleansing through food and drink might also contribute to the 
lower viral load of the OP as compared with the NP.
In paper II and IV the number of patients interviewed was appropriate, but
unfortunately the number of patients with a positive real time PCR for the included 
viruses was relatively low. However, in spite of the low numbers, we found a
significant difference in viral load both between the swab types and between the 
anatomical sites. In paper III, the patients were reswabbed a mean (SD) 1.5 ± 0.8 days 
after the initial swabbing. As expected, due to increasing viral clearance with time, 
some of the previous influenza virus positive patients tested negative at the time of the 
reswabbing.
Our results have implications for clinical practice. First, when harvesting samples for
respiratory viral diagnostics, NP samples are superior. The difference in viral load 
between the sites is so large that throat swabs should be recommended only in
extraordinary cases such as in patients with increased risk of bleeding or with 
anatomical malformations. Swab type has an impact on viral load, and flocked swabs 
retain more virus than rayon swabs and should be preferred over rayon swabs.
Secondly, routine testing for respiratory viruses are not recommended in elderly 
patients, as apparently, there is no impact on duration of stay or antibiotic use. Routine 
testing, during the influenza season is one exception, as available antiviral therapy is 
recommended in influenza patients with serious illness, regardless of age.
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10.4. Ethical consideration
The studies in this thesis were approved by the Regional Committee for Medical and 
Health Research Ethics (REK SØRØST).
Elderly individuals are in general positive to study inclusion [153], but are 
systematically underrepresented in clinical trials [154-156]. Non-inclusion of elderly
study-participants is problematic, as age-associated physiological and biological 
alterations make extrapolation of scientific results between age groups difficult [157].
Comorbidities are a major reason for exclusion from clinical trials [158]; most patients 
above 70 years of age suffer from at least two comorbid conditions [159]. In order to
accommodate for the heterogeneity in terms of general health, comorbidities and the 
possibility of death from non-study related causes in studies with  mainly elderly 
participants, elderly study populations should in general be larger than corresponding 
populations of younger participants[160].
Variable ability to provide informed consent is a challenge when conducting research 
in the elderly [161]. Acute confusional states are common in hospitalized elderly
populations [162] and these states are in some cases difficult to diagnose [163]. Non-
acknowledged acute confusion or cognitive impairment could result in inaccurate self-
reported patient data and ethically invalid informed consents.
In accordance with the Norwegian Law of Medical Research, research involving 
vulnerable patients groups should only be performed where the risk of the procedure 
for the patients is minimal and the person does not object to it[164]. Furthermore,
acquisition of the desired scientific data should be impossible through studies of less 
vulnerable patient groups[164]. In this thesis, ethical considerations were important 
both in study planning and execution. Immunosenescence renders the elderly 
particularly vulnerable to infections, and hence, scientific data acquired from studies in 
younger individuals may be less relevant for senior citizens.
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In this thesis, the level of cognitive impairment acceptable for inclusion varies with the 
different studies. TFNA is an invasive procedure, where the risk of pneumothorax is 
small, but still present. Thus, only patients able to give valid informed consent were 
included in the study. To ensure the validity of the consent, the patients were 
approached twice by a physician experienced in diagnosis of cognitive disorders. In 
addition, the attending nurses were interviewed and charts were reviewed for signs of 
confusion or cognitive impairment in the patient during hospitalization. For the studies 
involving NP and OP swabbing, the procedure itself is not harmful. The patients were 
approached by study technicians experienced in diagnosing cognitive impairment, and
in cases where doubts of the patients’ cognitive status, next of kin were asked to 
provide informed consent on behalf of the patient before sample harvesting. If the
patients orally or by body language signaled unwillingness to participate, sample 
harvesting were not performed.
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11. Perspectives
There is worldwide concern over increasing bacterial antibiotic resistance resulting 
mainly from unnecessary use of broad-spectrum antimicrobial drugs. Antibiotic 
treatment guided by exact etiological information would significantly reduce use of 
inappropriate antibiotics. Mixed infections are probably more common than realized,
and improved diagnostics could reduce this probably underestimated cause of 
treatment failures. Respiratory viral infections are frequent, and in the elderly viral 
infections might be overlooked due to atypical presentations. Some of these, notably
influenza, can now be successfully treated by specifically designed drugs.
Lately, the scientific community has shown increasing interest in the microbiome of 
the human body, including the lower airways[165]. Sampling of these microorganisms 
in the lungs by bronchoschopic methods is hampered by the risk of microbial 
contamination from the upper airways. To our knowledge no study has compared the 
feasibility of TNFA to that of bronchoalveolar lavage or protected sterile brush for 
mapping of the pulmonary microbiome.
Open lung biopsy is the gold standard for etiological diagnosis of CAP, but ethical as
well as medical considerations make this approach impossible in daily practice. 
Bridging the gap between the gold standard and the diagnostics methods in ordinary 
use, TFNA might have an important place in validation of new diagnostic tools. This is 
especially important when introducing new genetic assays, such as PCR targeting 
spn9802 or lytA in CAP [166, 167].  The dynamic nature of the microbiological flora 
and of drug resistance necessitates improved diagnostic tools for the etiology of CAP.
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For respiratory viral infections, little is known about the incidence in the oldest 
patients, mostly because adequate diagnostic measures are rarely applied. Thus, 
increased epidemiological research is important, especially in care facilities.  Within 
the next few years, a RS virus and probably also an adenovirus vaccine may become 
widely available. The prevalence and impact of RS and adenovirus infections in




1. TFNA was found to be feasible and safe in a Norwegian clinical research setting.
2. Nasopharyngeal specimens contained a higher viral load than specimens obtained 
from the oropharynx for the respiratory viruses in question.
3. Flocked swabs retained more virus than fiber swabs when harvesting samples for 
respiratory virus detection in the elderly.
4. Routine viral real time PCR in hospital admitted patients does not necessarily alter
length of stay or antibiotic treatment in hospitalized patients.
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13. Erratum
Paper II: The data for the study population are erroneous described in paper II. A total 
of 147 out of 173 symptomatic patients and 56 non-symptomatic patients (controls)
agreed to participate in the study. This had no impact on the results of the study.
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Forespørsel om deltagelse i forskningsprosjekt.
Vi ønsker herved å spørre deg om du vil delta i forskningsprosjektet ”Diagnostisk 
finnålsaspirasjon ved pneumoni oppstått utenfor sykehus”.
Lungebetennelse er en alminnelig sykdom som rammer de aller fleste i løpet av livet. I 
Norge behandles pasienter med denne sykdommen med antibiotika, og de fleste kommer 
seg fint ved denne behandlingen.
Imidlertid er hvilken bakterie eller virus som gir hver enkelt lungebetennelse mindre 
kjent, og vi finner ut dette hos mindre enn 50 % av pasientene som legges inn på sykehus.
I prosjektet ”Diagnostisk finnålsaspirasjon ved pneumoni oppstått utenfor sykehus”
ønsker vi å kartlegge hvilken bakterie eller virus som har gitt infeksjonen hos hver enkelt 
pasient. Funn av bakterier eller virus vil gi oss mulighet til å gi en mer målrettet og 
dermed mer effektiv behandling.
For å kunne delta i studien må man ha en lungebetennelse som er synlig på røntgenbildet, 
som ikke har oppstått på sykehus, og hvor man i tillegg har funn i blodprøver som støtter 
at dette er en lungebetennelse. Man kan ikke være med i studien dersom man har 
forlenget blødningstid (pga medisiner eller sykdom), eller hvis man har ekstremt dårlig 
lungefunksjon i utgangspunktet.
I tillegg til blodprøver, urinundersøkelser, halsprøver og slimprøver som gjøres av alle 
personer med lungebetennelse ønsker vi å utføre en lungeaspirasjon og en ekstra 
blodprøve 6 uker etter at du har vært innlagt ved sykehuset.
Lungeaspirasjon (finnålsaspirasjon) foregår ved at man under røntgengjennomlysning 
stikker en ultratynn nål inn i området hvor lungebetennelsen sitter, og suger ut litt 
vevsvæske. Selve innstikket varer i ca 20 sekunder, og er like ubehagelig som en 
blodprøve. Vevsvæsken blir sendt til undersøkelser ved mikrobiologisk avdeling for at 
man skal kunne bestemme hvilken bakterie eller virus som er i væsken. Når svaret 
foreligger vil man sammenholde dette med den behandlingen du allerede har fått, og så 
endre behandlingen hvis det viser seg at en annen behandling er mere hensiktsmessig.
Vi trenger også å ta en ekstra blodprøve ca 6 uker etter starten på din lungebetennelse for 
å se etter om du har fått antistoffer mot enkelte virus ( som kan ha forårsaket 
lungebetennelsen).
Lungeaspirasjon er en metode som er benyttet i flere europeiske land de siste 20 år, og 
har en lav bivirkningsprosent. Pneumothorax (luft i lungesekken som kan gjøre at deler 
av lungen trykkes noe sammen) oppstår hos ca 5 % av pasientene. Denne går som oftest 
over av seg selv. 1 av 200 pasienter kan komme til å trenge behandling for dette ( i form 
av et tynt rør som suger luften ut).




Deltagelse i prosjektet er frivillig, og selv om man takker ja kan man på et hvilket som 
helst tidspunkt trekke seg uten å oppgi grunn til dette. Dette vil ikke ha konsekvenser for 
ditt forhold til Sørlandet Sykehus HF.
Dersom du ikke ønsker å delta vil du få vår standard behandling ved lungebetennelser. Vi 
kan da ikke skreddersy behandlingen din ytterligere etter funn ved undersøkelsen.
Det vil bli opprettet en forskningsbiobank hvor man avidentifisert oppbevarer 2
blodprøver og noe av vevsvæsken fra lungebetennelsen i ti år. Prøvene i
forskningsbiobanken vil bli undersøkt på et senere tidspunkt. Ut i fra Biobankloven har 
du mulighet til å kalle tilbake ditt samtykke til bruk av disse prøvene når du måtte ønske 
dette. Beskjed om dette gis til prosjektleder (se telefonnummer på toppen av arket) som 
også er ansvarshavende for forskningsbiobanken. Etter ti år vil prøvene bli destruert.
Det vil bli opprettet et helseregister hvor prøveresultatene vil bli oppbevart og hvor hver 
deltager vil bli identifisert med et nummer, og intet navn. Koden til dette registeret er det 
bare prosjektleder, Susanne S. Hernes som har tilgang til. Resultatene av prøvene dine vil 
også bli oppbevart i din pasientjournal, slik at du selv har innsyn i disse. Vi vil fra din 
pasientjournal kun innhente opplysninger om hvor lenge du var innlagt på sykehuset 
under denne lungebetennelsen, samt resultater av de rutinemessige 
infeksjonsblodprøvene dine. Opplysningene vil bli behandlet konfidensielt, og de 
involverte parter har taushetsplikt.  Det vil ikke være mulig å identifisere deltagere i 
prosjektet når forskningsresultatet publiseres.
Prosjektet har blitt tilrådd av Regional Etisk Komite og er meldt til Personvern-ombudet 
for forskning, Norsk samfunnsvitenskapelig datatjeneste AS. Det er søkt om, og fått
tillatelse til oppretting av en forskningsbiobank fra Sosial- og Helsedepartementet.
Med vennlig hilsen











Jeg har mottatt skriftlig og muntlig informasjon om forskningsprosjektet ”Diagnostisk 
finnålsaspirasjon ved pneumoni oppstått utenfor sykehuset” og har sagt meg villig til 
å delta i dette.
________________________ ____________________________________
Dato/Sted Navn




”Diagnostisk finnålsaspirasjon ved pneumoni oppstått utefor sykehus”.
Hei !!
Håper du har kommet deg fint etter lungebetennelsen som du var innlagt på Sykehuset i 
Arendal med nylig.
Det er nå tid for en blodprøve i forbindelse med studien ”Diagnostisk finnålsaspirasjon ved 
pneumoni oppstått utenfor sykehus”. Blodprøven må tas en gang i tidsperioden uke ______ til  
________
Denne blodprøven kan du enten ta ved sykehusets laboratorium (i vanlig arbeidstid mandag til 
fredag klokken 0800-1500) eller hos din fastlege. Dersom du ønsker å ta blodprøven ved 
sykehuset i Arendal trenger du ikke å bestille time til dette. Ønsker du å ta den hos din 
fastlege bør du ta telefonisk kontakt med legekontoret for å høre om du trenger time til dette.
Blodprøven skal være gratis. Dersom du blir bedt om å betale for denne ber du legekontoret 
sende regningen direkte til meg (adressen står i vedlagte brev som er stilet til laboratoriet).
Jeg har fått resultatet på de prøvene som vi analyserer i forbindelse med innleggelsen din. 
Disse gir ikke noe sikkert svar på hvilken bakterie eller virus som ligger bak lungebetennelsen 
din. De resterende prøvene vil bli analysert i løpet av 2007.
Vedlagt ligger to ark som du skal levere på laboratoriet/hos fastlegen når du skal ta 
blodprøven.
Tusen takk for deltagelse i prosjektet!




”Diagnostisk finnålsaspirasjon ved pneumoni oppstått utefor sykehus”.
Til laboratoriet:
Denne pasienten er med i forskningsprosjektet ” Diagnostisk finnålsaspirasjon ved pneumoni 
oppstått utenfor sykehus”.
I forbindelse med prosjektet skal det tas en prøve med tanke på atypiske 
lungebetennelsesbakterier 4-6 uker etter sykehusinnleggelsen.
Vedlagt ligger ferdig utfylt rekvisisjon til prøveanalysering ved Mikrobiologisk laboratorium i 
Kristiansand. Det er særs viktig at prøvene sendes dit, og at man benytter vedlagte 
rekvisisjonsskjema. 
Dersom ditt laboratorium tar egenandel for å ta denne blodprøven skal ikke pasienten selv 






Dersom det oppstår andre spørsmål rundt dette kan jeg kontaktes på telefon 37014200.
Med vennlig hilsen
Susanne M. Sørensen Hernes
                                                               
”Diagnostisk finnålsaspirasjon ved pneumoni oppstått utenfor sykehus”
____________________________________________________________________________________






Sørlandet Sykehus Arendal, 30 november 2007
Hei
Tusen takk for at du i 2007 deltok i forskningsprosjektet ”Diagnostisk finnålsaspirasjon 
ved pneumoni oppstått utenfor sykehus” i forbindelse med at du hadde en 
lungebetennelse og var innlagt ved medisinsk avdeling, Sørlandet Sykehus Arendal.
Prosjektet er nå avsluttet, og vi holder på å analysere de siste prøvene.
Foreløpig har vi funnet ansvarlig bakterie eller virus hos 70 prosent av lungebetennelse, 
et resultat som vi er god fornøyde med.
Det gjenstår imidlertid enda noen analyser som vi vil gjøre på vevsvæsken fra lungen og 
blodprøvene. Det er dessverre ikke mulig å få utført disse analysene i Norge, og av den 
grunn må vi da sende prøvene ut av landet. 
Biobanklovens § 10 gjør det klart at dersom man vil sende prøver fra et 
forskningsprosjekt til utlandet, må hver enkelt deltager i prosjektet bli forespurt om 
tillatelse til dette.
Jeg vil med dette spørre deg om din tillatelse til at jeg kan sende prøvene dine til utlandet 
for analyse. Prøvene er avidentifisert, slik at det bare er jeg som kjenner til dine 
personlige data. 
En videre analyse i utlandet vil kunne gi oss verdifull informasjon om flere bakterier, 
som igjen vil gi oss uvurderlig informasjon.
Vedlagt ligger et samtykkeskjema for forsendelse av prøvene ut av landet. Dersom du gir 
din tillatelse er jeg takknemlig for at du returnerer dette skjemaet så raskt du kan. 
Samtykket må være skriftlig, men du står fritt til å bruke vedlagte frankerte 
svarkonvolutt, faks eller skanne det inn som et mailvedlegg.
Dersom du har spørsmål kan jeg nås på telefon 37 01 42 00.




                                                               
”Diagnostisk finnålsaspirasjon ved pneumoni oppstått utenfor sykehus”
____________________________________________________________________________________







Jeg er deltager i forskningsprosjektet ”Diagnostisk finnålsaspirasjon ved pneumoni 
oppstått utenfor sykehus” og gir herved min tillatelse til at blodprøver og vevsvæske tatt i 
forbindelse med dette forskningsprosjektet kan sendes ut av Norge for analyse.




Dette skjemaet kan  returneres på følgende måter:
i vedlagte frankerte svarkonvolutt.
Per faks til Susanne Hernes, Medisinsk ekspedisjon faksnr:
Som vedlegg til e-post til: Susanne.Sorensen.Hernes@sshf.no




Forespørsel om deltagelse i forskningsprosjekt.
Vi ønsker herved å spørre deg om du vil delta i forskningsprosjektet ”Lungebetennelse, 
veien videre” – virologi og ”atypiske agens”.
De fleste av oss blir syke av et luftveisvirus i løpet av livet. Vi vet at personer over 60 år 
er spesielt utsatt. Imidlertid er det vanskelig å med sikkerhet diagnostisere denne 
virusinfeksjonen. Vi vet ikke om man bør ta prøver fra hals eller nese, og heller ikke 
hvilken prøvepinne som bør benyttes. I denne studien ønsker vi å se om vi kan klare å 
finne svar på dette.
Alle pasienter født i 1948 eller før som blir innlagt ved medisinsk avdeling SSA en 
bestemt dag i uken vil bli forespurt om å bli med i studien, uavhengig av om man har 
tegn på en luftveisinfeksjon eller ikke.
Vi ønsker å ta en dyp neseprøve av deg og en halsprøve utført med to forskjellige 
prøvepinner. Denne undersøkelsen er ikke farlig, og gjøres rutinemessig ved de fleste 
sykehus i landet. I tillegg ønsker vi å ta en blodprøve for å undersøke om du har tegn på 
infeksjon med luftveisvirus. I tillegg vil 30 pasienter hvor vi finner virus, og 30 pasienter 
uten virus bli forespurt om frivillig videre oppfølgning etter 4 uker og 4 måneder.
Prøvene vil kunne bli analysert i utlandet (innenfor EU) .
Deltagelse i prosjektet er frivillig, og selv om man takker ja kan man på et hvilket som 
helst tidspunkt trekke seg uten å oppgi grunn til dette. Dette vil ikke ha konsekvenser for 
ditt forhold til Sørlandet Sykehus HF.
Dersom du ikke ønsker å delta vil du få vår standard behandling under oppholdet.
Det vil bli opprettet et helseregister hvor prøveresultatene vil bli oppbevart og hvor hver 
deltager vil bli identifisert med et nummer, og intet navn. Koden til dette registeret er det 
bare prosjektleder, Susanne S. Hernes som har tilgang til. Resultatene av prøvene dine vil 
bli tilført din pasientjournal, slik at du selv har innsyn i disse. Vi vil fra din pasientjournal 
kun innhente opplysninger vedrørende denne sykehusinnleggelsen. Opplysningene vil bli 
behandlet konfidensielt, og de involverte parter har taushetsplikt.  Det vil ikke være 
mulig å identifisere deltagere i prosjektet når forskningsresultatet publiseres. 
Prosjektet avsluttes senest ved utgangen av 2009.
Prosjektet har blitt tilrådd av Regional Etisk Komite og er meldt til Personvernombudet 
for forskning, Norsk samfunnsvitenskapelig datatjeneste AS. 
Med vennlig hilsen









Jeg har mottatt skriftlig og muntlig informasjon om forskningsprosjektet  
”Lungebetennelse, veien videre- virologi og ”atypiske agens” ” og har sagt meg villig 
til å delta i dette.
________________________ ____________________________________
Dato/Sted Navn
”Lungebetennelse veien videre”- Virologiske og ”atypiske” agens
1. Pasientnr____________                                                         
2. Inklusjonsdato ___________________
3. Alder _________                 
utdeling av medisiner
-4 tilsyn per dag.
syn per dag.
8. Innleggelsesdiagnose: _______________________________________________________
9. Tidspunkt for innleggelse på sykehus: kl (0-24) ___:___
10. -
11 . Rtg thorax v innkomst:
Cancer
12. Sykdomsforløp: Antall dager syk _____________    
13






”Lungebetennelse veien videre”- Virologiske og ”atypiske” agens
16.Medikamenter:
17 18 19.Antall per uke_____________________
20              21. Mengde per uke__________________
Vaksinasjonsstatus:
22. Influensa sist _____________________   23. Pneumokokkvaksine_________________
24).CRP______________  25). Høyeste under oppholdet___________
26).Kreatinin_________    27). Hvite __________    28). Urea______________
29. VEKT   _____________       30.Høyde _______________   
31.Vektendring siste 6 mnd _______
32. EPIKRISEDIAGNOSE
Diagnoser ved utreise:   _____________________________________________________
_______________________________________________________
33 Antall dager innlagt: _______ 






”Lungebetennelse veien videre”- Virologiske og ”atypiske” agens
36. Sannsynlig infeksjon:   
37. Bærertilstand:                  
Prøvetagning ved Influensa A infeksjon – Hoveddel – 2.desember 2009
Forespørsel om deltakelse i forskningsprosjektet
”Prøvetagning ved Influensa A infeksjon”
Bakgrunn og hensikt
Dette er et spørsmål til deg om å delta i en forskningsstudie for å undersøke om det er best å ta prøver 
fra nese eller hals når man har influensa. Dette er et viktig spørsmål for at vi skal kunne tilby pasienter 
med mistenkt influensasykdom best mulig helsehjelp.
Hva innebærer studien?
Det vil bli tatt en penselprøve fra hals og en fra nesen i dag. I tillegg ønsker vi å undersøke blodprøven 
som ble tatt av deg ved innkomst til sykehuset, samt spørre deg om du kan ta en ny blodprøve etter fire 
uker (hos din egen lege). Kun personer som allerede har fått påvist en influensainfeksjon kan være med 
i studien. 
Studien vil ikke påvirke den behandlingen du allerede får ved sykehuset. Dersom du velger å ikke være 
med vil dette ikke påvirke ditt forhold til sykehuset.
Mulige fordeler og ulemper
Penselprøver fra hals og nese er begge rutineundersøkelser ved norske sykehus i dag. Studien vil ikke 
medføre noen ulemper for deltagerne.
Hva skjer med prøvene og informasjonen om deg
Prøvene tatt av deg og informasjonen som registreres om deg skal kun brukes slik som beskrevet i 
hensikten med studien. Alle opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer 
eller andre direkte gjenkjennende opplysninger. En kode knytter deg til dine opplysninger og prøver 
gjennom en navneliste
Det er kun autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne 
tilbake til deg. Prøvene og informasjonen om deg vil bli slettet senest i 2025.
Det vil ikke være mulig å identifisere deg i resultatene av studien når disse publiseres.
Frivillig deltakelse
Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke ditt samtykke 
til å delta i studien. Dette vil ikke få konsekvenser for din videre behandling. Dersom du ønsker å delta, 
undertegner du samtykkeerklæringen på siste side. Om du nå sier ja til å delta, kan du senere trekke 
tilbake ditt samtykke uten at det påvirker din øvrige behandling. Dersom du senere ønsker å trekke deg 
eller har spørsmål til studien, kan du kontakte prosjektleder Susanne Hernes (37014200)
Ytterligere informasjon om studien finnes i kapittel A – utdypende forklaring av hva studien 
innebærer.
Ytterligere informasjon om biobank, personvern og forsikring finnes i kapittel B – Personvern, 
biobank, økonomi og forsikring.
Samtykkeerklæring følger etter kapittel B.
Prøvetagning ved Influensa A infeksjon – Kapittel A og B – 2.desember 2009
Kapittel A- utdypende forklaring av hva studien innebærer
Personer som er innlagt med Influensa ved Sørlandet Sykehus HF vil bli forespurt om å delta i studien.  
Man kan ikke delta dersom man er under 18 år, eller dersom man har forlenget blødningstid (INR>3)
Ved prøvetagning for influensa er det anbefalt enten penselprøve fra hals eller nese. Vi vet ikke med 
sikkerhet om disse to prøvene er like gode, og det er det vi ønsker å undersøke i denne studien.
Deltagelse i studien medfører kun at det tas en penselprøve fra hals og en fra nese som en 
engangsforeteelse under sykehusinnleggelsen. Penselprøver fra hals og nese er rutineundersøkelser på 
norske sykehus og medfører ingen bivirkninger.
Kapittel B - Personvern, biobank, økonomi og forsikring
Personvern
Opplysninger som registreres om deg er opplysninger om den aktuelle sykehistorien din (dvs hvor
lenge du har vært syk, hvilke symptomer du har hatt, resultater av blodprøver, hvor lenge du var 
innlagt på sykehus og hvordan det har gått med deg etter at du har blitt skrevet ut). Navnelisten vil bli 
koblet mot Dødsårsaksregisteret.
Formålet er å kontrollere at studieopplysningene stemmer overens med tilsvarende opplysninger i din 
journal. Alle som får innsyn har taushetsplikt. 
Sørlandet Sykehus HF ved administrerende direktør er databehandlingsansvarlig.
Biobank
Pensel-prøvene og blodprøvene som blir tatt og informasjonen utledet av dette materialet vil bli lagret 
i en forskningsbiobank ved Sørlandet Sykehus HF. Hvis du sier ja til å delta i studien, gir du også 
samtykke til at det biologiske materialet og analyseresultater inngår i biobanken. Susanne Hernes er 
ansvarshavende for forskningsbiobanken. Biobanken planlegges å vare til 2025. Etter dette vil 
materialet og opplysninger bli destruert og slettet etter interne retningslinjer. 
Utlevering av materiale og opplysninger til andre
Hvis du sier ja til å delta i studien, gir du også ditt samtykke til at prøver og avidentifiserte 
opplysninger utleveres til andre forskere innen for EU hvor formålet er influensaforskning. 
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver
Hvis du sier ja til å delta i studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om 
deg. Du har videre rett til å få korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du 
trekker deg fra studien, kan du kreve å få slettet innsamlede prøver og opplysninger, med mindre 
opplysningene allerede er inngått i analyser eller brukt i vitenskapelige publikasjoner. 
Økonomi 
Studien og biobanken er finansiert gjennom forskningsmidler fra Sørlandet Sykehus HF.
Prøvetagning ved Influensa A infeksjon – Kapittel A og B – 2.desember 2009
Informasjon om utfallet av studien
Du har rett til å få informasjon om utfallet i studien. Dette kan du få ved å kontakte prosjektleder.
Samtykke til deltakelse i studien
Jeg er villig til å delta i studien 
----------------------------------------------------------------------------------------------------------------
(Signert av prosjektdeltaker, dato)
Stedfortredende samtykke når berettiget, enten i tillegg til personen selv eller istedenfor
(Signert av nærstående, dato)
Jeg bekrefter å ha gitt informasjon om studien
----------------------------------------------------------------------------------------------------------------
(Signert, rolle i studien, dato)
04.11.2009
PASIENTARK
PRØVETAGNING VED INFLUENSA A INFEKSJON
(fylles ut av den som tar prøven)
Pasientnr Pasientmerkelapp
Prøven tatt: _______________________(dato)  Tatt av  HQ/ RH
Prøve ved innkomst tatt fra (ring rundt)    Hals         Nese           Husker ikke
H1N1 vaksine tatt:  J/N        Dato dose 1_______________    Dato dose 2 _______________
Sesonginfluensavaksine tatt J/N     Dato/årstall _____________
Pneumokokkvaksine tatt  J/N         Dato/årstall______________
SENDES SUSANNE I INTERNPOSTEN (lukket konvolutt)
Susanne Hernes, Medisinsk avdeling SSA
Prøvetagning ved Influensa A infeksjon - Blodprøver
”Prøvetagning ved Influensa infeksjon”
Kjære deltager!
Jeg håper du har kommet deg etter sykehusinnleggelsen og har gjenopptatt normal aktivitet.
I forbindelse med deltagelsen din i forskningsprosjektet er det nå tid for å ta en siste blodprøve.
Vi ønsker å se på dannelsen av antistoffer mot influensa, noe vi gjør når vi sammenligner blodprøven 
ved sykehusinnleggelsen med denne siste blodprøven. Dette vil gi oss verdifull informasjon om 
beskyttelse mot influensainfeksjoner, og også effekt av eventuell vaksine. Kunnskap om beskyttende 
antistoffer vil komme alle influensapasienter til god.
Jeg vil av den grunn be deg om å ta en ny blodprøve i løpet av en uke. Blodprøven kan tas hos din 
fastlege eller ved sykehusets laboratorieavdeling (åpningstid 0800-1500 alle hverdager). Prøven er 
gratis, og skal ikke koste deg noe.
Ta med dette arket (med klistremerker) til laboratoriet, slik at de som tar prøven får den informasjonen 
de trenger.
Jeg vil med dette takke deg for deltagelse i studien.
Dersom du har noen spørsmål kan jeg nås på telefon 37 01 42 00.
Med vennlig hilsen
Susanne S Hernes, prosjektleder.
Medisinsk avdeling
Sørlandet Sykehus Arendal.
Prøvetagning ved Influensa A infeksjon - Blodprøver
Til laboratoriet
Pasienten er deltager i et forskningsprosjekt vedrørende prøvetagning ved Influensa 
infeksjon.
I den forbindelse skal det tas blodprøve ca fire uker etter sykehusinnleggelsen.
1.Ta to gelglass og sentrifuger disse innen to timer. Merk glassene med pasientens navn, 
fødselsnummer og dato for prøvetagning. I tillegg merkes glassene med vedlagte 
klistrelapper (sett de på tvers).
2. Send prøvene til :





Eller via hentetjenesten dersom dere er tilknyttet denne (som går til SSA)
3. Legg ved dette skjemaet.
På forhånd takk for hjelpen. 
Dersom det påløper noen kostnader for pasienten i forbindelse med prøvetagningen ber 
jeg om at regning sendes til meg.
Med vennlig hilsen
Susanne Hernes
Medisinsk avdeling
Sørlandet Sykehus Arendal
Til Laboratorieavdelingen SSA
Sett prøvene kaldt.
Fryses av Gunn/Kirsti.
